Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Leslie Citrome. (2017) Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Review of Neurotherapeutics 17:10, pages 1029-1043.
Read now
Read now
Georgios Schoretsanitis, Edoardo Spina, Christoph Hiemke & Jose de Leon. (2017) A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Review of Clinical Pharmacology 10:9, pages 965-981.
Read now
Read now
Leslie Citrome. (2013) New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Review of Neurotherapeutics 13:7, pages 767-783.
Read now
Read now
Pierre Chue & James Chue. (2012) A review of paliperidone palmitate. Expert Review of Neurotherapeutics 12:12, pages 1383-1397.
Read now
Read now
Peter Bräunig, Emilio Sacchetti & Rossella Medori. (2008) Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study. International Journal of Psychiatry in Clinical Practice 12:1, pages 74-77.
Read now
Read now
Pierre-Michel Llorca, Jean-Pierre Kahn, Véronique Moreau-Mallet, Philippe Bouhours & the French StoRMi investigators group. (2006) Symptom control, functioning, and hospitalization status in French patients changed from oral atypical antipsychotics to risperidone long-acting injectable. International Journal of Psychiatry in Clinical Practice 10:4, pages 276-284.
Read now
Read now
Beat Nick, Roland Vauth, Daniel Braendle, Anita Riecher-Rössler & THE SWISS StoRMi INVESTIGATORS GROUP. (2006) Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable. International Journal of Psychiatry in Clinical Practice 10:3, pages 174-181.
Read now
Read now
Articles from other publishers (13)
Harshita Gupta, Rutu Panchal, Niyati Acharya & Priti Jignesh Mehta. (2020) Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs. Current Psychiatry Research and Reviews 16:1, pages 42-59.
Crossref
Crossref
Linfeng Wu, Dileep R. Janagam, Timothy D. Mandrell, James R. Johnson & Tao L. Lowe. (2015) Long-Acting Injectable Hormonal Dosage Forms for Contraception. Pharmaceutical Research 32:7, pages 2180-2191.
Crossref
Crossref
Archana Rawat, Erika Stippler, Vinod P. Shah & Diane J. Burgess. (2011) Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal® Consta®. International Journal of Pharmaceutics 420:2, pages 198-205.
Crossref
Crossref
P.-M. Llorca, P. Bouhours & V. Moreau-Mallet. (2008) Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. L'Encéphale 34:2, pages 170-178.
Crossref
Crossref
M. -N. Vacheron & F. Caroli. (2008) Prise en charge du premier épisode psychotique : le patient partenaireFirst-episode psychosis management: the patient as a partner. PSN 6:1, pages 26-30.
Crossref
Crossref
Pierre Chue & Robin Emsley. (2007) Long-Acting Formulations of Atypical Antipsychotics. CNS Drugs 21:6, pages 441-448.
Crossref
Crossref
Monique P Curran & Gillian M Keating. (2006) Management of Schizophrenia. Disease Management & Health Outcomes 14:2, pages 107-125.
Crossref
Crossref
Roland Vauth & Rolf-Dieter Stieglitz. (2006) Der Stellenwert von Kombinationsbehandlung in der Versorgung schizophrener Störungen. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie 54:3, pages 173-183.
Crossref
Crossref
P. S. Chue, Bart M. S. Heeg, Erik Buskens & Ben A. van Hout. (2012) Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. PharmacoEconomics 23:S1, pages 62-74.
Crossref
Crossref
Serdar Dursun. (2016) An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia. Journal of Psychopharmacology 19:5_suppl, pages 3-4.
Crossref
Crossref
W. Kissling, S. Heres, K. Lloyd, E. Sacchetti, P. Bouhours, R. Medori & P. M. Llorca. (2016) Direct transition to long-acting risperidone - analysis of long-term efficacy. Journal of Psychopharmacology 19:5_suppl, pages 15-21.
Crossref
Crossref
Hans-J??rgen M??ller, Pierre-Michel Llorca, Emilio Sacchetti, Stephen D Martin, Rossella Medori & Eduard Parellada. (2005) Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology 20:3, pages 121-130.
Crossref
Crossref
Luiz Paulo de C. Bechelli. (2003) Antipsicóticos de ação prolongada no tratamento de manutenção da esquizofrenia. Parte II. O manejo do medicamento, integração da equipe multidisciplinar e perspectivas com a formulação de antipsicóticos de nova geração de ação prolongada. Revista Latino-Americana de Enfermagem 11:4, pages 507-515.
Crossref
Crossref